All In Biotech

Drug Trial Radar · NCT04724980

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

A Phase 1/2 Study of Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

38

Actual

Start

Mar 16, 2021

Primary completion

Jun 5, 2024

Study completion Jun 5, 2026

Sponsor

Lead sponsor
Precigen, IncIndustry
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI)
First posted
Jan 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 study in patients with a Recurrent Respiratory Papillomatosis (RRP) disease burden that requires repeated surgical procedures for management. RRP is a rare disease caused by the human papillomavirus (HPV). Participants with a pathologically confirmed diagnosis of papilloma and a clinical diagnosis of RRP will be screened for this protocol.

Conditions

  • Recurrent Respiratory Papillomatosis
  • Papillomavirus Infections
  • Papillomaviridae

Interventions

  • PRGN-2012 - Phase I; Dose Level 1Drug

    In Phase 1, dose level 1 of the clinical trial, PRGN-2012 is administered at 1 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.

  • PRGN-2012 - Phase I; Dose Level 2Drug

    In Phase 1, dose level 2 of the clinical trial, PRGN-2012 is administered at 5 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.

  • PRGN-2012 - Phase II; Dose Level 2Drug

    The Phase 2 portion is designed as a dose expansion study where patients are treated at the RP2D of 5 x 10\^11 PU.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the percentage of subjects with a complete response following treatment with PRGN-2012Time frame: 1 year
  2. Determine the incidence of dose limiting toxicities to evaluate safety and identify RP2D of PRGN-2012Time frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.